放化疗同步治疗Ⅲ期非小细胞肺癌.DOCVIP

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
临床医学论文-放化疗同步治疗Ⅲ期非小细胞肺癌 ???????????????????? 作者:杨志诚 何永萍 唐志 杨志雄 黄杰 【关键词】? 放化 ??? 摘要:目的:评价放射治疗合不同化疗方案的治疗不能手术的ш期非小细胞肺癌(NSCLC)疗效。方法:62例不能手术的ш期NSCLC患者随机分为2个组;29例化疗组每周接受1次紫杉醇30mg,顺铂30mg化疗(紫杉醇组),33例为对照组。连续5~6周,均同时配合常规分割放射冶疗(2Gy/次,5次/周),照射野包括肺部原发灶和纵隔淋巴引流区,总剂里为60~70Gy。结果:紫杉醇组总有效率(CR+PR)为82.8%,完全缓解(CR)率为10.3%,对照组总有效率为54.6%,CR率为18.0%。2个组总有效率差异有显著性意义(X2=4.41 p=0.038)。中位生存期1、2年生存率紫杉醇组分别为12.8个月,52.2%、27.3%,对照组分别为9.8个月、42.8%、18.4%,2个组差异无显著性意义。化疗的毒副作用主要是骨髓抑制和消化道反应,但均可耐受。结论:紫杉醇组绐疗不能手术的3期NSCLC近期有效率明显优于单放组,但不提高生存率。 ??? 关键词:非小细胞肺癌/放射疗法;非小细胞肺癌/药物疗法;综合治疗 ??? Concomitant Chemotherapy and Radiotherapy for Inoperable Stage 3 Non-small Cell Lung Cancer ??? Abstract:Objective: To evaluate the effect of concomitantdifferent regimens chemotherapy and radiotherapy for inoperable stage 3 non-small cell lung cancr (NSCLC),Methods Fron September 1998 to December 2000,62 patients winth inoperable stage 3 NSCLC were randomized into groups.Method:Nine patients received paclitaxel 30mg and cisplain 30 mg weekly for 5~6 weeks(paclitaxel group ),and 33 patients was control group.All patients received concomitant radiotherapy as well.Radiotherapy was given withconventional fraction in 2 Gy per fraction and five fractions per week .The total tumor doses were 60~70Gy .Treatment fields covered clinical umor and lymph node invlolved .Result: The overall response (CR+PR) rate in paclitaxel group was 82.% with a coplete response (CR) rate of 10.3%.The overall response rate in the control group was 54.6%with a CR rate of 18% .The difference of overall response rate between the two groups was statistically significant (P0.05) the median survival time ,1-,and 2-year survival rates were 12.8monthe ,52.2%and 27.2%for paclitaxel group ,and 9.8 months ,42.8% and 18.4% for the control group(P0.05).the major toxic effects of chemotherapy were gastrointestinal tract reactine and myelosuppression .Conclusion: Concomitant chemotherapy of paclitaxel plus cisplatin and radiotherapy for inoperable stage 3 NSCLC is acceptable

文档评论(0)

fengyu11 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档